Arno Therapeutics, Inc Form 4 September 08, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB APPROVAL

OMB Number: 3235-0287

Expires: January 31, 2005

0.5

Estimated average burden hours per response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading SUSSMAN S DONALD Issuer Symbol Arno Therapeutics, Inc [ARNI] (Check all applicable) (First) (Middle) (Last) 3. Date of Earliest Transaction Director (Month/Day/Year) X__ 10% Owner _X_ Other (specify Officer (give title C/O HEWLETT BAY 08/15/2016 below) below) ASSOCIATES LLC, 800 See Footnote 1 WESTCHESTER AVENUE, SUITE S-414 (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting RYE BROOK, NY 10573 (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired 5. Amount of 7. Nature of Indirect Security (Month/Day/Year) Execution Date, if Transaction(A) or Disposed of (D) Securities Ownership (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: Beneficial (Month/Day/Year) (Instr. 8) Owned Direct (D) Ownership Following or Indirect (Instr. 4) Reported (I) (A) Transaction(s) (Instr. 4) (Instr. 3 and 4) Code V Price Amount (D) Common 08/15/2016 P 714,285 714,285 D Α (2)Stock By Commercial Common 4,472,905 I Street Stock Capital, LLC

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(1)(3)

Edgar Filing: Arno Therapeutics, Inc - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

6. Date Exercisable and

Expiration Date

5. Number of

SEC 1474 (9-02)

7. Title and Amount of

Underlying Securities

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

4.

3. Transaction Date 3A. Deemed

Conversion (Month/Day/Year) Execution Date, if TransactionDerivative

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) Disposed of ((Instr. 3, 4, ar 5)	or (D)	(Month/Day/Year)		4)
				Code V	(A) (Date (D) Exercisable	Expiration Date	Title	Amount Number Shares
2016 Series F Warrants (right to buy)	\$ 0.4375	08/15/2016		P	357,142	08/15/2016	08/15/2021	Common Stock	357,1
2012 Series A Warrants	\$ 1.17 (4)					10/29/2013	11/26/2017	Common Stock	1,780, (4)
2013 Series D	\$ 1.81 <u>(4)</u>					10/29/2013	10/29/2018	Common Stock	1,523, (4)

Reporting Owners

Reporting Owner Name / Address	Relationships					
reporting owner runter runters	Director	10% Owner	Officer	Other		
SUSSMAN S DONALD						
C/O HEWLETT BAY ASSOCIATES LLC		X		See		
800 WESTCHESTER AVENUE, SUITE S-414	-414 X		Footnote 1			
RYE BROOK, NY 10573						

Signatures

Warrants

1. Title of

Derivative

2.

/s/ Christopher J. Melsha as Attorney-in-Fact for S. Donald Sussman pursuant to Power of Attorney filed herewith.

09/08/2016

**Signature of Reporting Person

Date

Reporting Owners 2

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- CSC has a contractual right to designate one member of the Issuer's board of directors and has designated Steven B. Ruchefsky, a director (1) of the Issuer, pursuant to such right. Accordingly, the Reporting Person, as a co-managing director of CSC, may be deemed to be a director by deputization for purposes of Section 16 of the Exchange Act.
- (2) The reported securities are included within 714,285 Issuer units purchased by the Reporting Person for \$0.35 per unit. Each unit consists of one share of common stock and a 2016 Series F Warrant to purchase one-half share of common stock.
- Represents securities of the Issuer directly held by Commercial Street Capital LLC ("CSC"). The Reporting Person is a co-managing member of CSC and as such may be deemed to beneficially own the securities held by CSC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- As a result of the Issuer's 8/15/16 private placement of common stock and Series F Warrants, the exercise prices and shares underlying

 (4) the 2012 Series A Warrants and 2013 Series D Warrants were automatically adjusted to the exercise price and shares reflected pursuant to anti-dilution adjustment provisions in such warrants.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.